Article in Stroke, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
35 authors.
Rakesh B Patel *Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine (R.B.P., M.K., I.B., A. Jain, A. Jha, N.D., B.S., A.K.C.), University of Iowa, Iowa City.ORCID 0000-0001-9727-9738
Mariia Kumskova *Division of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine (R.B.P., M.K., I.B., A. Jain, A. Jha, N.D., B.S., A.K.C.), University of Iowa, Iowa City.ORCID 0000-0002-2477-3011
Hanish KodaliDepartment of Population Health Science and Policy, Icahn School of Medicine, Mount Sinai, New York, NY (H.K., M.A.D.).ORCID 0000-0002-8229-4369
Ivan BudnikDivision of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine (R.B.P., M.K., I.B., A. Jain, A. Jha, N.D., B.S., A.K.C.), University of Iowa, Iowa City.ORCID 0000-0002-6652-2667
Aditi JainDivision of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine (R.B.P., M.K., I.B., A. Jain, A. Jha, N.D., B.S., A.K.C.), University of Iowa, Iowa City.ORCID 0000-0003-2237-3249
Abhishek JhaDivision of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine (R.B.P., M.K., I.B., A. Jain, A. Jha, N.D., B.S., A.K.C.), University of Iowa, Iowa City.ORCID 0000-0001-9229-0612
Daniel ThedensDepartment of Radiology, Carver College of Medicine (D.T.), University of Iowa, Iowa City.ORCID 0000-0002-4704-3185
Nirav DhaneshaDivision of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine (R.B.P., M.K., I.B., A. Jain, A. Jha, N.D., B.S., A.K.C.), University of Iowa, Iowa City.ORCID 0000-0001-9268-4363
Brijesh SutariyaDivision of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine (R.B.P., M.K., I.B., A. Jain, A. Jha, N.D., B.S., A.K.C.), University of Iowa, Iowa City.ORCID 0000-0001-8602-0966
Karisma A NagarkattiDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine (K.A.N., J.L., P.D.L.), University of Southern California, Los Angeles.ORCID 0000-0002-7300-9968
Jessica LambDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine (K.A.N., J.L., P.D.L.), University of Southern California, Los Angeles.ORCID 0000-0002-0342-9983
Pradip KamatDepartment of Neurology, Medical College of Georgia, Augusta University (P.K., M.B.K., K.D., D.C.H.).ORCID 0000-0002-0376-2284
Yanrong ShiDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD (Y.S., B.A., R.C.K.).ORCID 0000-0002-3144-5569
Brooklyn AveryDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD (Y.S., B.A., R.C.K.).ORCID 0009-0009-7093-7580
Takahiko ImaiDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (T.I., X.J., C.A.).ORCID 0000-0002-4422-2946
Xuyan JinDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (T.I., X.J., C.A.).ORCID 0009-0003-1923-4923
Anjali ChauhanDepartment of Neurology, McGovern Medical School, University of Texas HSC, Houston (A. Chauhan, L.D.M., J.A.).ORCID 0000-0002-9825-8100
Ligia S B BoisserandDepartment of Neurology, Yale University School of Medicine, New Haven, CT (L.S.B.B., L.H.S.).ORCID 0000-0002-0058-2894
Mohammad B KhanDepartment of Neurology, Medical College of Georgia, Augusta University (P.K., M.B.K., K.D., D.C.H.).ORCID 0000-0001-8231-1256
Krishnan DhandapaniDepartment of Neurology, Medical College of Georgia, Augusta University (P.K., M.B.K., K.D., D.C.H.).ORCID 0000-0001-7044-1117
Basavaraju G SanganahalliDepartments of Radiology and Biomedical Imaging, Yale University, New Haven, CT (B.G.S.).ORCID 0000-0002-0851-6621
Lauren H SansingDepartment of Neurology, Yale University School of Medicine, New Haven, CT (L.S.B.B., L.H.S.).ORCID 0000-0002-6898-1680
David C HessDepartment of Neurology, Medical College of Georgia, Augusta University (P.K., M.B.K., K.D., D.C.H.).ORCID 0000-0002-8345-9153
Raymond C KoehlerDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, MD (Y.S., B.A., R.C.K.).ORCID 0000-0002-5890-9992
Louise D McCulloughDepartment of Neurology, McGovern Medical School, University of Texas HSC, Houston (A. Chauhan, L.D.M., J.A.).ORCID 0000-0002-8050-1686
Jaroslaw AronowskiDepartment of Neurology, McGovern Medical School, University of Texas HSC, Houston (A. Chauhan, L.D.M., J.A.).ORCID 0000-0002-9256-7973
Cenk AyataDepartment of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (T.I., X.J., C.A.).ORCID 0000-0002-3644-6042
Márcio A DinizDepartment of Population Health Science and Policy, Icahn School of Medicine, Mount Sinai, New York, NY (H.K., M.A.D.).ORCID 0000-0002-2427-7843
Patrick D LydenDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine (K.A.N., J.L., P.D.L.), University of Southern California, Los Angeles.ORCID 0000-0001-6170-4042
Anna M PlanasInstitute of Biomedical Research of Barcelona (IIBB), Spanish National Research Council (CSIC) (A.M.P.).ORCID 0000-0002-6147-1880
Angel ChamorroDepartment of Neurology, Carver College of Medicine (A. Chamorro, E.C.L.), University of Iowa, Iowa City.ORCID 0000-0002-0392-6285
Anil K ChauhanDivision of Hematology, Oncology and Blood & Marrow Transplantation, Department of Internal Medicine, Carver College of Medicine (R.B.P., M.K., I.B., A. Jain, A. Jha, N.D., B.S., A.K.C.), University of Iowa, Iowa City.ORCID 0000-0001-8554-0898
Enrique C LeiraDepartment of Neurology, Carver College of Medicine (A. Chamorro, E.C.L.), University of Iowa, Iowa City.ORCID 0000-0003-3695-2946
SPAN Investigators
Funding
Targeting Pyruvate Kinase M2: A novel strategy to combat thrombo-inflammationR35HL139926 · NHLBI · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR · 2018 to 2024
$5.3M
The NIH SPAN Coordinating CenterU24NS113452 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LYDEN, PATRICK D · 2019 to 2021
$2.4M
Wnt Signaling in StrokeR01NS105894 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KOEHLER, RAYMOND CHARLES · 2018 to 2022
$2.3M
Microglia/macrophage polarization after intracerebral hemorrhageR01NS102583 · NINDS · JOHNS HOPKINS UNIVERSITY · PI KOEHLER, RAYMOND CHARLES · 2018 to 2021
$1.8M
The University of Iowa Stroke Preclinical Assessment Network to Support Translational Studies for Acute CerebroprotectionU01NS130587 · NINDS · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR, LEIRA, ENRIQUE CARLOS · 2023 to 2025
$1.8M
Mechanisms of Chronic Remote Ischemic Conditioning Induced Cerebroprotection in a VCID ModelR01NS099455 · NINDS · AUGUSTA UNIVERSITY · PI HESS, DAVID C. · 2017 to 2020
$1.5M
Rheoerythrocrine dysfunction in stroke and remote ischemic conditioning (REDS)R01NS112511 · NINDS · AUGUSTA UNIVERSITY · PI HESS, DAVID C. · 2020 to 2023
$1.3M
Yale site for Stroke Preclinical Assessment Network (SPAN) for Acute NeuroprotectionU01NS113445 · NINDS · YALE UNIVERSITY · PI SANSING, LAUREN H · 2019 to 2021
$1.2M
Multicenter preclinical trial of rho-kinase inhibitor fasudil in acute focal cerebral ischemia and reperfusionU01NS113443 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI AYATA, CENK · 2019 to 2021
$1.2M
Stroke Preclinical Assessment Network (SPAN) – Tacilizumab for treatment of acute ischemic strokeU01NS113451 · NINDS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI ARONOWSKI, JAROSLAW · 2019 to 2021
$1.1M
The University of Iowa Stroke Preclinical Assessment Center for Neuroprotection in strokeU01NS113388 · NINDS · UNIVERSITY OF IOWA · PI CHAUHAN, ANIL KUMAR, LEIRA, ENRIQUE CARLOS · 2019 to 2021
$1.1M
Remote Ischemic Conditioning: A collateral therapeutic and neuroprotectantU01NS113356 · NINDS · AUGUSTA UNIVERSITY · PI HESS, DAVID C. · 2019 to 2021
backgroundPast failures in translating stroke cerebroprotection provoked calls for a more rigorous methodological approach, leading to the stroke preclinical assessment network SPAN (Stroke Preclinical Assessment Network), where uric acid (UA) treatment exceeded a prespecified efficacy boundary for the primary functional outcome. Still, successful translation to humans requires confirmation of the effect of UA across key biological variables relevant to patients with stroke.
methodsWe measured the effects of intravenous UA treatment (16 mg/kg) versus intravenous saline in groups of animals enrolled in the SPAN network with diverse comorbidities, sex, and age. The masked study drug or placebo was administered during reperfusion in rodents undergoing a transient middle cerebral artery filament occlusion. The primary outcome was the modified corner test index at day 30 poststroke, and numerous secondary outcomes were collected. A modified intention-to-treat population was used in the analysis. We tested for any interactions with sex, age, and comorbidities (obesity-induced hyperglycemia and hypertension).
resultsIn total, 710 animals were randomized to receive either intravenous UA or saline. After accounting for procedural dropouts and exclusions from treatment, a total of 687 animals were qualified and analyzed, including 458 assigned to UA and 229 to intravenous saline control. UA-treated animals exhibited a better primary functional outcome at day 30 (probability, 0.56 [95% CI, 0.52-0.60];
conclusionsUA provides ischemic stroke cerebroprotection across key relevant biological variables, making it a promising intervention to be further tested in human clinical trials.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Uric Acid Stroke Cerebroprotection Transcended Sex, Age, and Comorbidities in a Multicenter Preclinical Trial. · full record | OpenQuestion